SCHEMBL7713256

SCHEMBL7713256

CC1Oc2ccc(CN(Cc3cccc(F)c3)C(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 0.48
HSD17B10 Q99714 2/20 0.38
ALOX15 P16050 1/20 0.38
RIPK1 Q13546 1/20 0.37
SMYD3 Q9H7B4 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
MAPK1 P28482 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
THRB P10828 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708149 0.92 PARP1 (0.45) PARP1HSD17B10ALOX15SMYD3ALDH1A1
SCHEMBL6305893 0.91 PARP1 (0.54) PARP1HSD17B10ALOX15SMYD3ALDH1A1
SCHEMBL7713376 0.91 PARP1 (0.56) PARP1HSD17B10ALOX15SMYD3ALDH1A1
SCHEMBL7712797 0.90 RIPK1 (0.36) PARP1HSD17B10ALOX15RIPK1MEN1
SCHEMBL7708224 0.89 PARP1 (0.46) PARP1HSD17B10ALOX15SMYD3ALDH1A1
SCHEMBL7711139 0.89 PARP1 (0.48) PARP1HSD17B10ALOX15RIPK1SMYD3
SCHEMBL7711093 0.88 PARP1 (0.47) PARP1HSD17B10ALOX15SMYD3MEN1
SCHEMBL6302723 0.88 PARP1 (0.47) PARP1HSD17B10ALOX15RIPK1SMYD3
SCHEMBL7708088 0.88 PARP1 (0.47) PARP1HSD17B10ALOX15SMYD3ALDH1A1
SCHEMBL6308969 0.87 PARP1 (0.46) PARP1HSD17B10ALOX15SMYD3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed